11β-Hydroxysteroid Dehydrogenase 1: Translational and Therapeutic Aspects

Endocrine Reviews

Volumn 34, Issue 4, 2013, Pages 525-555

  Gathercole, Laura L ^a   Lavery, Gareth G ^a   Morgan, Stuart A ^a   Cooper, Mark S ^a   Sinclair, Alexandra J ^a   Tomlinson, Jeremy W ^a   Stewart, Paul M ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 11BETA HYDROXYSTEROID DEHYDROGENASE 1 INHIBITOR; 3ALPHA(OR 20BETA) HYDROXYSTEROID DEHYDROGENASE; CORTISONE; ENZYME INHIBITOR; GLUCOCORTICOID; HYDROCORTISONE; UNCLASSIFIED DRUG;

COGNITIVE DEFECT; DRUG ACTIVITY; DRUG INDICATION; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME INHIBITION; ENZYMOLOGY; GLAUCOMA; HUMAN; INTRACRANIAL HYPERTENSION; METABOLIC SYNDROME X; MOLECULAR BIOLOGY; NONHUMAN; OSTEOPOROSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

EID: 84882789718     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2012-1050     Document Type: Review

References (318)

1. Munck A, Naray-Fejes-Toth A. The ups and downs of glucocorticoid physiology. Permissive and suppressive effects revisited. Mol Cell Endocrinol. 1992;90:C1-C4.
2. Cope CL, Black EG. The behaviour of 14c-cortisol and estimation of cortisol production rate in man. Clin Sci (Lond). 1958;17:147-163.
3. Esteban NV, Loughlin T, Yergey AL, et al. Daily cortisol production rate in man determined by stable isotope dilu-tion/mass spectrometry. J Clin Endocrinol Metab. 1991; 72:39-45.
4. Siiteri PK, Murai JT, Hammond GL, Nisker JA, Raymoure WJ, Kuhn RW. The serum transport of steroid hormones. Recent Prog Horm Res. 1982;38:457-510.
5. Meulenberg PM, Hofman JA. Differences between concentrations of salivary cortisol and cortisone and of free cortisol and cortisone in plasma during pregnancy and postpartum. Clin Chem. 1990;36:70-75.
6. Monder C, Shackleton CH. 11 β-Hydroxysteroid dehydrogenase: fact or fancy? Steroids. 1984;44:383-417.
7. Monder C, White PC. 11 β-Hydroxysteroid dehydrogenase. Vitam Horm. 1993;47:187-271.
8. Kendell EC. Cortisone: Memoirs of a hormone hunter. New York, NY: Charles Scribner's Sons. 1971;121-137.
9. Tomlinson JW, Walker EA, Bujalska IJ, et al. 11β-Hydroxysteroid dehydrogenase type 1.a tissue-specific regulator of glucocorticoid response Endocr Rev. 2004; 25:831-866.
10. Edwards CR, Stewart PM, Burt D, et al. Localisation of 11 β-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet. 1988;2: 986-989.
11. White PC, Mune T, Rogerson FM, Kayes KM, Agarwal AK. Molecular analysis of 11 β-hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess. Steroids. 1997;62:83-88.
12. Stewart PM, Krozowski ZS. 11 β-Hydroxysteroid dehydrogenase. Vitam Horm. 1999;57:249-324.
13. Odermatt A, Arnold P, Stauffer A, Frey BM, Frey FJ. The N-terminal anchor sequences of 11β-hydroxysteroid dehydrogenases determine their orientation in the endoplasmic reticulum membrane. J Biol Chem. 1999;274:28762-28770.
14. Ozols J. Lumenal orientation and posttranslational modifications of the liver microsomal 11-β-hydroxysteroid dehydrogenase. J Biol Chem. 1995;270:2305-2312.
15. Agarwal AK, Monder C, Eckstein B, White PC. Cloning and expression of rat cDNA encoding corticosteroid 11 β-dehydrogenase. J Biol Chem. 1989;264:18939-18943.
16. Lakshmi V, Monder C. Purification and characterization of the corticosteroid 11 β-dehydrogenase component of the rat liver 11 β-hydroxysteroid dehydrogenase complex. Endocrinology. 1988;123:2390-2398.
17. Monder C, Lakshmi V. Evidence for kinetically distinct forms of corticosteroid 11 β-dehydrogenase in rat liver microsomes. J Steroid Biochem. 1989;32:77-83.
18. Maser E, Volker B, Friebertshauser J. 11β-hydroxysteroid dehydrogenase type 1 from human liver: dimerization and enzyme cooperativity support its postulated role as glucocorticoid reductase. Biochemistry. 2002;41:2459-2465.
19. Stewart PM, Murry BA, Mason JI. Human kidney 11 β-hydroxysteroid dehydrogenase is a high affinity nicotinamide adenine dinucleotide-dependent enzyme and differs from the cloned type I isoform. J Clin Endocrinol Metab. 1994;79:480-484.
20. Tannin GM, Agarwal AK, Monder C, New MI, White PC. The human gene for 11 β-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization. J Biol Chem. 1991;266:16653-16658.
21. Bujalska IJ, Walker EA, HewisonM,Stewart PM.Aswitch in dehydrogenase to reductase activity of 11 β-hydroxysteroid dehydrogenase type 1 upon differentiation ofhuman omental adipose stromal cells. J Clin Endocrinol Metab. 2002;87:1205-1210.
22. Seckl JR, Walker BR. Minireview: 11β-hydroxysteroid dehydrogenase type 1-a tissue-specific amplifier of glucocorticoid action. Endocrinology. 2001;142:1371-1376.
23. Jellinck PH, Pavlides C, Sakai RR, McEwen BS. 11 β-hydroxysteroid dehydrogenase functions reversibly as an oxidoreductase in the rat hippocampus in vivo. J Steroid Biochem Mol Biol. 1999;71:139-144.
24. Draper N, Walker EA, Bujalska IJ, et al. Mutations in the genes encoding 11β-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nat Genet. 2003;34:434-439.
25. Monder C, Lakshmi V. Corticosteroid 11 β-dehydrogenase of rat tissues: immunological studies. Endocrinology. 1990;126:2435-2443.
26. Lavery GG, Walker EA, Tiganescu A, et al. Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiency. J Clin Endocrinol Metab. 2008;93:3827-3832.
27. Lavery GG, Hauton D, Hewitt KN, et al. Hypoglycemia with enhanced hepatic glycogen synthesis in recombinant mice lacking hexose-6-phosphate dehydrogenase. Endocrinology. 2007;148:6100-6106.
28. Rogoff D, Ryder JW, Black K, et al. Abnormalities of glucose homeostasis and the hypothalamic-pituitary-adrenal axis in mice lacking hexose-6-phosphate dehydrogenase. Endocrinology. 2007;148:5072-5080.
29. Walker EA, Ahmed A, Lavery GG, et al. 11β-Hydroxysteroid dehydrogenase type 1 regulation by intracellular glucose 6-phosphate provides evidence for a novel link between glucose metabolism and hypothalamo-pituitaryadrenal axis function. J Biol Chem. 2007;282:27030-27036.
30. Abrahams L, SemjonousNM,Guest P, et al. Biomarkers of hypothalamic-pituitary-adrenal axis activity in mice lacking 11β-HSD1 and H6PDH. J Endocrinol. 2012;214:367-372.
31. Lawson AJ, Walker EA, Lavery GG, et al. Cortisonereductase deficiency associated with heterozygous mutations in 11β-hydroxysteroid dehydrogenase type 1. Proc Natl Acad Sci USA. 2011;108:4111-4116.
32. Lavery GG, Idkowiak J, Sherlock M, et al. Novel H6PDH mutations in two girls with premature adrenarche: 'apparent' and 'true'CRDcan be differentiated by urinary steroid profiling. Eur J Endocrinol. 2013;168:K19-K26.
33. Harris HJ, Kotelevtsev Y, Mullins JJ, Seckl JR, Holmes MC. Intracellular regeneration of glucocorticoids by 11β-hydroxysteroid dehydrogenase (11β-HSD)-1 plays a key role in regulation of the hypothalamic-pituitary-adrenal axis: analysis of 11β-HSD-1-deficient mice. Endocrinology. 2001;142:114-120.
34. Semjonous NM, Sherlock M, Jeyasuria P, et al. Hexose-6-phosphate dehydrogenase contributes to skeletal muscle homeostasis independent of 11β-hydroxysteroid dehydrogenase type 1. Endocrinology. 2011;152:93-102.
35. Carter RN, Paterson JM, Tworowska U, et al. Hypotha lamic-pituitary-adrenal axis abnormalities in response to deletion of 11β-HSD1 is strain-dependent. J Neuroendocrinol. 2009;21:879-887.
36. Lakshmi V, Sakai RR, McEwen BS, Monder C. Regional distribution of 11 β-hydroxysteroid dehydrogenase in rat brain. Endocrinology. 1991;128:1741-1748.
37. Moisan MP, Seckl JR, Edwards CR. 11 β-Hydroxysteroid dehydrogenase bioactivity and messengerRNAexpression in rat forebrain: localization in hypothalamus, hippocampus, and cortex. Endocrinology. 1990;127:1450-1455.
38. Lavery GG, Zielinska AE, Gathercole LL, et al. Lack of significant metabolic abnormalities in mice with liverspecific disruption of 11β-hydroxysteroid dehydrogenase type 1. Endocrinology. 2012;153:3236-3248.
39. Paterson JM, Morton NM, Fievet C, et al. Metabolic syndrome without obesity: hepatic overexpression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci USA. 2004;101:7088-7093.
40. Draper N, Powell BL, Franks S, Conway GS, Stewart PM, McCarthy MI. Variants implicated in cortisone reductase deficiency do not contribute to susceptibility to common forms of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2006;65:64-70.
41. Chua AK, Azziz R, Goodarzi MO. Association study of CYP17 and HSD11B1 in polycystic ovary syndrome utilizing comprehensive gene coverage. Mol Hum Reprod. 2012;18:320-324.
42. Valkenburg O, Uitterlinden AG, Themmen AP, et al. Genetic polymorphisms of the glucocorticoid receptor may affect the phenotype of women with anovulatory polycystic ovary syndrome. Hum Reprod. 2011;26:2902-2911.
43. Smit P, Dekker MJ, de Jong FJ, et al. Lack of association of the 11 β-hydroxysteroid dehydrogenase type 1 gene 83,557insA and hexose-6-phosphate dehydrogenase gene R453Q polymorphisms with body composition, adrenal androgen production, blood pressure, glucose metabolism, and dementia. J Clin Endocrinol Metab. 2007;92:359-362.
44. White PC. Genotypes at 11β-hydroxysteroid dehydrogenase type 11B1 and hexose-6-phosphate dehydrogenase loci are not risk factors for apparent cortisone reductase deficiency in a large population-based sample. J Clin Endocrinol Metab. 2005;90:5880-5883.
45. San Millan JL, Botella-Carretero JI, Alvarez-Blasco F, et al. A study of the hexose-6-phosphate dehydrogenase gene R453Q and 11 β-hydroxysteroid dehydrogenase type 1 gene 83557insA polymorphisms in the polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:4157-4162.
46. Gambineri A, Vicennati V, Genghini S, et al. Genetic variation in 11β-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:2295-2302.
47. Gambineri A, Tomassoni F, Munarini A, et al. A combination of polymorphisms in HSD11B1 associates with in vivo 11β-HSD1 activity and metabolic syndrome in women with and without polycystic ovary syndrome. Eur J Endocrinol. 2011;165:283-292.
48. de Quervain DJ, Poirier R, Wollmer MA, et al. Glucocorticoid-related genetic susceptibility for Alzheimer's disease. Hum Mol Genet. 2004;13:47-52.
49. Dekker MJ, Tiemeier H, Luijendijk HJ, et al. The effect of common genetic variation in 11β-hydroxysteroid dehydrogenase type 1 on hypothalamic-pituitary-adrenal axis activity and incident depression. J Clin Endocrinol Metab. 2012;97:E233-E237.
50. Deary IJ, Hayward C, Permana PA, et al. Polymorphisms in the gene encoding 11B-hydroxysteroid dehydrogenase type 1 (HSD 11B1) and lifetime cognitive change. Neurosci Lett. 2006;393:74-77.
51. Gelernter-Yaniv L, Feng N, Sebring NG, Hochberg Z, Yanovski JA. Associations between a polymorphism in the 11 β hydroxysteroid dehydrogenase type I gene and body composition. Int J Obes Relat Metab Disord. 2003;27: 983-986.
52. Olza J, Gil-Campos M, Leis R, et al. A gene variant of 11β-hydroxysteroid dehydrogenase type 1 is associated with obesity in children. Int J Obes (Lond). 2012;36: 1558-1563.
53. Nair S, Lee YH, Lindsay RS, et al. 11β-Hydroxysteroid dehydrogenase type 1: genetic polymorphisms are associated with type 2 diabetes in Pima Indians independently of obesity and expression in adipocyte and muscle. Diabetologia. 2004;47:1088-1095.
54. Franks PW, Knowler WC, Nair S, et al. Interaction between an 11βHSD1 gene variant and birth era modifies the risk of hypertension in Pima Indians. Hypertension. 2004; 44:681-688.
55. Dujic T, Bego T, Mlinar B, et al. Association between 11β-hydroxysteroid dehydrogenase type 1 gene polymorphisms and metabolic syndrome in Bosnian population. Biochem Med (Zagreb). 2012;22:76-85.
56. Hwang JY, Lee SH, Kim GS, et al. HSD11B1 polymorphisms predicted bone mineral density and fracture risk in postmenopausal women without a clinically apparent hypercortisolemia. Bone. 2009;45:1098-1103.
57. Rahman TJ, Mayosi BM, Hall D, et al. Common variation at the 11-β hydroxysteroid dehydrogenase type 1 gene is associated with left ventricular mass. Circ Cardiovasc Genet. 2011;4:156-162.
58. Qin KN, Rosenfield RL. Mutations of the hexose-6-phosphate dehydrogenase gene rarely cause hyperandrogenemic polycystic ovary syndrome. Steroids. 2011;76:135-139.
59. Martinez-Garcia MA, San-Millan JL, Escobar-Morreale HF. The R453Q and D151A polymorphisms of hexose-6-phosphate dehydrogenase gene (H6PD) influence the polycystic ovary syndrome (PCOS) and obesity. Gene. 2012; 497:38-44.
60. RahmanTJ, Walker EA, MayosiBM,et al. Genotype at the P554L variant of the hexose-6 phosphate dehydrogenase gene is associated with carotid intima-medial thickness. PLoS One. 2011;6:e23248.
61. Newport M, Sirugo G, Lyons E, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet. 2007;39:1329-1337.
62. Alcina A, Fernandez O, Gonzalez JR, et al. Tag-SNP analysis of the GFI1-EVI5-RPL5-FAM69 risk locus for multiple sclerosis. Eur J Hum Genet. 2010;18:827-831.
63. Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Obes Res. 1994;2:486-508.
64. Houssay BA, Smyth FS, Foglia VG, Houssay AB. Comparative diabetogenic action of the hypophysis from various animals. J Exp Med. 1942;75:93-106.
65. Long CN, Lukens FD. The effects of adrenalectomy and hypophysectomy upon experimental diabetes in the cat. J Exp Med. 1936;63:465-490.
66. Ingle DJ, Meeks RC. Comparison of some metabolic and morphologic effects of cortisone and hydrocortisone given by continuous injection to rats. Am J Physiol. 1952;170: 77-80.
67. Ingle DJ. Some further studies on the relationship of adrenal cortical hormones to experimental diabetes. Diabetes. 1952;1:345-350.
68. Long CN. The endocrine control of the blood-sugar. Lancet. 1952;262:325-329.
69. Gathercole LL, Stewart PM. Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes. J Steroid Biochem Mol Biol. 2010;122:21-27.
70. Fraser R, Ingram MC, Anderson NH, Morrison C, Davies E, Connell JM. Cortisol effects on body mass, blood pressure, and cholesterol in the general population. Hypertension. 1999;33:1364-1368.
71. Marin P, Darin N, Amemiya T, Andersson B, Jern S, Bjorntorp P. Cortisol secretion in relation to body fat distribution in obese premenopausal women. Metabolism. 1992; 41:882-886.
72. Lottenberg SA, Giannella-Neto D, Derendorf H, et al. Effect of fat distribution on the pharmacokinetics of cortisol in obesity. Int J Clin Pharmacol Ther. 1998;36:501-505.
73. Pasquali R, Biscotti D, Spinucci G, et al. Pulsatile secretion of ACTH and cortisol in premenopausal women: effect of obesity and body fat distribution. Clin Endocrinol (Oxf). 1998;48:603-612.
74. Ljung T, Andersson B, Bengtsson BA, Bjorntorp P, Marin P. Inhibition of cortisol secretion by dexamethasone in relation to body fat distribution: a dose-response study. Obes Res. 1996;4:277-282.
75. Stewart PM, Boulton A, Kumar S, Clark PM, Shackleton CH. Cortisol metabolism in human obesity: impaired cortisone3cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab. 1999;84:1022-1027.
76. Valsamakis G, Anwar A, Tomlinson JW, et al. 11β-Hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2004;89:4755-4761.
77. Targher G, Bertolini L, Zoppini G, Zenari L, Falezza G. Relationship of non-alcoholic hepatic steatosis to cortisol secretion in diet-controlled type 2 diabetic patients. Diabet Med. 2005;22:1146-1150.
78. Westerbacka J, Yki-Jarvinen H, Vehkavaara S, et al. Body fat distribution and cortisol metabolism in healthy men: enhanced 5β-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver. J Clin Endocrinol Metab. 2003;88:4924-4931.
79. Targher G, Bertolini L, Rodella S, Zoppini G, Zenari L, Falezza G. Associations between liver histology and cortisol secretion in subjects with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf). 2006;64:337-341.
80. Zoppini G, Targher G, Venturi C, Zamboni C, MuggeoM. Relationship of nonalcoholic hepatic steatosis to overnight low-dose dexamethasone suppression test in obese individuals. Clin Endocrinol (Oxf). 2004;61:711-715.
81. Wu Z, Bucher NL, Farmer SR. Induction of peroxisome proliferator-activated receptor γ during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPβ, C/EBPδ, and glucocorticoids. Mol Cell Biol. 1996;16: 4128-4136.
82. Cao Z, Umek RM, McKnight SL. Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells. Genes Dev. 1991;5:1538-1552.
83. Gregoire F, Genart C, Hauser N, Remacle C. Glucocorticoids induce a drastic inhibition of proliferation and stimulate differentiation of adult rat fat cell precursors. Exp Cell Res. 1991;196:270-278.
84. Bader T, Zoumakis E, Friedberg M, Hiroi N, Chrousos GP, Hochberg Z. Human adipose tissue under in vitro inhibition of 11β-hydroxysteroid dehydrogenase type 1: differentiation and metabolism changes. Horm Metab Res. 2002;34:752-757.
85. Slavin BG, Ong JM, Kern PA. Hormonal regulation of hormone-sensitive lipase activity and mRNA levels in isolated rat adipocytes. J Lipid Res. 1994;35:1535-1541.
86. Villena JA, Roy S, Sarkadi-Nagy E, Kim KH, Sul HS. Desnutrin, an adipocyte gene encoding a novel patatin domaincontaining protein, is induced by fasting and glucocorticoids: ectopic expression of desnutrin increases triglyceride hydrolysis. J Biol Chem. 2004;279:47066-47075.
87. Gathercole LL, Morgan SA, Bujalska IJ, Hauton D, Stewart PM, Tomlinson JW. Regulation of lipogenesis by glucocorticoids and insulin in human adipose tissue. PLoS One. 2011;6:e26223.
88. Nechushtan H, Benvenisty N, Brandeis R, Reshef L. Glucocorticoids control phosphoenolpyruvate carboxykinase gene expression in a tissue specific manner. Nucleic Acids Res. 1987;15:6405-6417.
89. Olswang Y, Blum B, Cassuto H, et al. Glucocorticoids repress transcription of phosphoenolpyruvate carboxykinase (GTP) gene in adipocytes by inhibiting its C/EBPmediated activation. J Biol Chem. 2003;278:12929-12936.
90. Wang Y, Jones VB, Urs S, et al. The human fatty acid synthase gene and de novo lipogenesis are coordinately regulated in human adipose tissue. J Nutr. 2004;134: 1032-1038.
91. Ashby P, Robinson DS. Effects of insulin, glucocorticoids and adrenaline on the activity of rat adipose-tissue lipoprotein lipids. Biochem J. 1980;188:185-192.
92. Buren J, Liu HX, Jensen J, Eriksson JW. Dexamethasone impairs insulin signalling and glucose transport by depletion of insulin receptor substrate-1, phosphatidylinositol 3-kinase and protein kinase B in primary cultured rat adipocytes. Eur J Endocrinol. 2002;146:419-429.
93. Lundgren M, Buren J, Ruge T, Myrnas T, Eriksson JW. Glucocorticoids down-regulate glucose uptake capacity and insulin-signaling proteins in omental but not subcutaneous human adipocytes. J Clin Endocrinol Metab. 2004; 89:2989-2997.
94. Sakoda H, Ogihara T, Anai M, et al. Dexamethasoneinduced insulin resistance in 3T3-L1 adipocytes is due to inhibition of glucose transport rather than insulin signal transduction. Diabetes. 2000;49:1700-1708.
95. Turnbow MA, Keller SR, Rice KM, Garner CW. Dexamethasone down-regulation of insulin receptor substrate-1 in 3T3-L1 adipocytes. J Biol Chem. 1994;269:2516-2520.
96. Gathercole LL, Bujalska IJ, Stewart PM, Tomlinson JW. Glucocorticoid modulation of insulin signaling in human subcutaneous adipose tissue. J Clin Endocrinol Metab. 2007;92:4332-4339.
97. Tomlinson JJ, Boudreau A, Wu DM, et al. Insulin sensitization of human preadipocytes through glucocorticoid hormone induction of forkhead transcription factors. Mol Endocrinol. 2010;24:104-113.
98. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect "Cushing's disease of the omentum"? Lancet. 1997; 349:1210-1213.
99. Quirk SJ, Slattery JA, Funder JW. Epithelial and adipose cells isolated from mammary glands of pregnant and lactating rats differ in 11 β-hydroxysteroid dehydrogenase activity. J Steroid Biochem Mol Biol. 1990;37:529-534.
100. Tomlinson JW, Moore J, Cooper MS, et al. Regulation of expression of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines. Endocrinology. 2001;142:1982-1989.
101. Handoko K, Yang K, Strutt B, Khalil W, Killinger D. Insulin attenuates the stimulatory effects of tumor necrosis factor α on 11β-hydroxysteroid dehydrogenase 1 in human adipose stromal cells. J Steroid Biochem Mol Biol. 2000;72:163-168.
102. Friedberg M, Zoumakis E, Hiroi N, Bader T, Chrousos GP, Hochberg Z. Modulation of 11 β-hydroxysteroid dehydrogenase type 1 in mature human subcutaneous adipocytes by hypothalamic messengers. J Clin Endocrinol Metab. 2003;88:385-393.
103. Veilleux A, Rheaume C, Daris M, Luu-The V, Tchernof A. Omental adipose tissue type 1 11 β-hydroxysteroid dehydrogenase oxoreductase activity, body fat distribution, and metabolic alterations in women. J Clin Endocrinol Metab. 2009;94:3550-3557.
104. Bujalska IJ, Gathercole LL, Tomlinson JW, et al. A novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis. J Endocrinol. 2008; 197:297-307.
105. Bujalska IJ, Kumar S, Hewison M, Stewart PM. Differentiation of adipose stromal cells: the roles of glucocorticoids and 11β-hydroxysteroid dehydrogenase. Endocrinology. 1999;140:3188-3196.
106. Livingstone DE, Kenyon CJ, Walker BR. Mechanisms of dysregulation of 11 β-hydroxysteroid dehydrogenase type 1 in obese Zucker rats. J Endocrinol. 2000;167:533-539.
107. Livingstone DE, Jones GC, Smith K, et al. Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology. 2000;141:560-563.
108. Prasad SS, Prashanth A, Kumar CP, Reddy SJ, Giridharan NV, Vajreswari A. A novel genetically-obese rat model with elevated 11 β-hydroxysteroid dehydrogenase type 1 activity in subcutaneous adipose tissue. Lipids Health Dis. 2010;9:132.
109. Nakano S, Inada Y, Masuzaki H, et al. Bezafibrate regulates the expression and enzyme activity of 11 β-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab. 2007;292:E1213-E1222.
110. Drake AJ, Livingstone DE, Andrew R, Seckl JR, Morton NM, Walker BR. Reduced adipose glucocorticoid reactivation and increased hepatic glucocorticoid clearance as an early adaptation to high-fat feeding in Wistar rats. Endocrinology. 2005;146:913-919.
111. Engeli S, Bohnke J, Feldpausch M, et al. Regulation of 11β-HSD genes in human adipose tissue: influence of central obesity and weight loss. Obes Res. 2004;12:9-17.
112. Goedecke JH, Wake DJ, Levitt NS, et al. Glucocorticoid metabolism within superficial subcutaneous rather than visceral adipose tissue is associated with features of the metabolic syndrome in South African women. Clin Endocrinol (Oxf). 2006;65:81-87.
113. Kannisto K, Pietilainen KH, Ehrenborg E, et al. Overexpression of 11β-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins. J Clin Endocrinol Metab. 2004;89:4414-4421.
114. Lindsay RS, Wake DJ, Nair S, et al. Subcutaneous adipose 11 β-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. J Clin Endocrinol Metab. 2003;88:2738-2744.
115. Paulmyer-Lacroix O, Boullu S, Oliver C, AlessiMC,Grino M. Expression of the mRNA coding for 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. J Clin Endocrinol Metab. 2002;87:2701-2705.
116. Rask E, Olsson T, Soderberg S, et al. Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab. 2001;86:1418-1421.
117. Rask E, Walker BR, Soderberg S, et al. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11β-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab. 2002;87:3330-3336.
118. Sandeep TC, Andrew R, Homer NZ, Andrews RC, Smith K, Walker BR. Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. Diabetes. 2005;54:872-879.
119. Baudrand R, Carvajal CA, Riquelme A, et al. Overexpression of 11β-hydroxysteroid dehydrogenase type 1 in hepatic and visceral adipose tissue is associated with metabolic disorders in morbidly obese patients. Obes Surg. 2010;20:77-83.
120. Desbriere R, Vuaroqueaux V, Achard V, et al. 11β-Hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity (Silver Spring). 2006;14:794-798.
121. Michailidou Z, Jensen MD, Dumesic DA, et al. Omental 11β-hydroxysteroid dehydrogenase 1 correlates with fat cell size independently of obesity. Obesity (Silver Spring). 2007;15:1155-1163.
122. Paulsen SK, Pedersen SB, Fisker S, Richelsen B. 11β-HSD type 1 expression in human adipose tissue: impact of gender, obesity, and fat localization. Obesity (Silver Spring). 2007;15:1954-1960.
123. Tomlinson JW, Sinha B, Bujalska I, Hewison M, Stewart PM. Expression of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. J Clin Endocrinol Metab. 2002;87:5630-5635.
124. Kotelevtsev Y, Holmes MC, Burchell A, et al. 11β-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA. 1997;94:14924-14929.
125. Morton NM, Paterson JM, Masuzaki H, et al. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 β-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes. 2004;53:931-938.
126. Ehehalt R, Fullekrug J, Pohl J, Ring A, Herrmann T, Stremmel W. Translocation of long chain fatty acids across the plasma membrane-lipid rafts and fatty acid transport proteins. Mol Cell Biochem. 2006;284:135-140.
127. Maeda K, Cao H, Kono K, et al. Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab. 2005;1: 107-119.
128. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science. 2001;294:2166-2170.
129. Masuzaki H, Yamamoto H, Kenyon CJ, et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest. 2003; 112:83-90.
130. Kershaw EE, MortonNM,Dhillon H, Ramage L, Seckl JR, Flier JS. Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity. Diabetes. 2005;54: 1023-1031.
131. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917-923.
132. Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol. 2004;2:1048-1058.
133. Rockall AG, Sohaib SA, Evans D, et al. Hepatic steatosis in Cushing's syndrome: a radiological assessment using computed tomography. Eur J Endocrinol. 2003;149:543-548.
134. Dourakis SP, Sevastianos VA, Kaliopi P. Acute severe steatohepatitis related to prednisolone therapy. Am J Gastroenterol. 2002;97:1074-1075.
135. Nanki T, Koike R, Miyasaka N. Subacute severe steatohepatitis during prednisolone therapy for systemic lupus erythematosis. Am J Gastroenterol. 1999;94:3379.
136. Amatruda JM, Danahy SA, Chang CL. The effects of glucocorticoids on insulin-stimulated lipogenesis in primary cultures of rat hepatocytes. Biochem J. 1983;212:135-141.
137. Zhao LF, Iwasaki Y, Zhe W, et al. Hormonal regulation of acetyl-CoA carboxylase isoenzyme gene transcription. Endocr J. 2010;57:317-324.
138. Dolinsky VW, Douglas DN, Lehner R, Vance DE. Regulation of the enzymes of hepatic microsomal triacylglycerol lipolysis and re-esterification by the glucocorticoid dexamethasone. Biochem J. 2004;378:967-974.
139. Baxter JD, Forsham PH. Tissue effects of glucocorticoids. Am J Med. 1972;53:573-589.
140. Schwarz JM, Linfoot P, Dare D, Aghajanian K. Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr. 2003;77:43-50.
141. Ricketts ML, Verhaeg JM, Bujalska I, Howie AJ, Rainey WE, Stewart PM. Immunohistochemical localization of type 1 11β-hydroxysteroid dehydrogenase in human tissues. J Clin Endocrinol Metab. 1998;83:1325-1335.
142. Jamieson PM, Chapman KE, Edwards CR, Seckl JR. 11 β-Hydroxysteroid dehydrogenase is an exclusive 11 β-reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations. Endocrinology. 1995;136:4754-4761.
143. Ricketts ML, Shoesmith KJ, Hewison M, Strain A, Eggo MC, Stewart PM. Regulation of 11 β-hydroxysteroid dehydrogenase type 1 in primary cultures of rat and human hepatocytes. J Endocrinol. 1998;156:159-168.
144. Torrecilla E, Fernandez-Vazquez G, Vicent D, et al. Liver upregulation of genes involved in cortisol production and action is associated with metabolic syndrome in morbidly obese patients. Obes Surg. 2012;22:478-486.
145. Konopelska S, Kienitz T, Hughes B, et al. Hepatic 11β-HSD1 mRNA expression in fatty liver and nonalcoholic steatohepatitis. Clin Endocrinol (Oxf). 2009;70:554-560.
146. Candia R, Riquelme A, Baudrand R, et al. Overexpression of 11β-hydroxysteroid dehydrogenase type 1 in visceral adipose tissue and portal hypercortisolism in non-alcoholic fatty liver disease. Liver Int. 2012;32:392-399.
147. Ahmed A, Rabbitt E, Brady T, et al. A switch in hepatic cortisol metabolism across the spectrum of non alcoholic fatty liver disease. PLoS One. 2012;7:e29531.
148. Liu Y, Nakagawa Y, Wang Y, et al. Increased glucocorticoid receptor and 11β-hydroxysteroid dehydrogenase type 1 expression in hepatocytes may contribute to the phenotype of type 2 diabetes in db/db mice. Diabetes. 2005;54: 32-40.
149. Morton NM, Holmes MC, Fievet C, et al. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11β-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem. 2001;276:41293-41300.
150. Dimitriadis G, Leighton B, Parry-Billings M, et al. Effects of glucocorticoid excess on the sensitivity of glucose transport and metabolism to insulin in rat skeletal muscle. Biochem J. 1997;321:707-712.
151. Morgan SA, Sherlock M, Gathercole LL, et al. 11β-Hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle. Diabetes. 2009;58:2506-2015.
152. Salehzadeh F, Al-Khalili L, Kulkarni SS, Wang M, Lönnqvist F, Krook A. Glucocorticoid-mediated effects on metabolism are reversed by targeting 11 β hydroxysteroid dehydrogenase type 1 in human skeletal muscle. Diabetes Metab Res Rev. 2009;25:250-258.
153. Zhang M, Lv XY, Li J, Xu ZG, Chen L. Alteration of 11 β-hydroxysteroid dehydrogenase type 1 in skeletal muscle in a rat model of type 2 diabetes. Mol Cell Biochem. 2009; 324:147-155.
154. Abdallah BM, Beck-Nielsen H, Gaster M. Increased expression of 11β-hydroxysteroid dehydrogenase type 1 in type 2 diabetic myotubes. Eur J Clin Invest. 2005;35:627-634. doi: 10.1210/er.2012-1050 edrv.endojournals.org 549
155. Whorwood CB, Donovan SJ, Wood PJ, Phillips DI. Regulation of glucocorticoid receptor α and β isoforms and type I 11β-hydroxysteroid dehydrogenase expression in human skeletal muscle cells: a key role in the pathogenesis of insulin resistance? J Clin Endocrinol Metab. 2001;6: 2296-2308.
156. Rafacho A, Abrantes JL, Ribeiro DL, et al. Morphofunctional alterations in endocrine pancreas of short-and longterm dexamethasone-treated rats.HormMetab Res. 2011; 43:275-281.
157. Gerich JE. Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop type 2 diabetes? Diabetes. 2002;51(suppl 1):S117-S121.
158. Seino S, Shibasaki T, Minami K. Dynamics of insulin secretion and the clinical implications for obesity and diabetes. J Clin Invest. 2011;121:2118-2125.
159. Swali A, Walker EA, Lavery GG, Tomlinson JW, Stewart PM. 11β-Hydroxysteroid dehydrogenase type 1 regulates insulin and glucagon secretion in pancreatic islets. Diabetologia. 2008;51:2003-2011.
160. Lambillotte C, Gilon P, Henquin JC. Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. J Clin Invest. 1997;99: 414-423.
161. Ortsater H, Alberts P, Warpman U, Engblom LO, Abrahmsen L, Bergsten P. Regulation of 11 β-hydroxysteroid dehydrogenase type 1 and glucose-stimulated insulin secretion in pancreatic islets of Langerhans. Diabetes Metab Res Rev. 2005;21:359-366.
162. Hult M, Ortsater H, Schuster G, et al. Short-term glucocorticoid treatment increases insulin secretion in islets derived from lean mice through multiple pathways and mechanisms. Mol Cell Endocrinol. 2009;301:109-116.
163. Delaunay F, Khan A, Cintra A, et al. Pancreatic β cells are important targets for the diabetogenic effects of glucocorticoids. J Clin Invest. 1997;100:2094-2098.
164. Schmid J, Ludwig B, Schally AV, et al. Modulation of pancreatic islets-stress axis by hypothalamic releasing hormones and 11β-hydroxysteroid dehydrogenase. Proc Natl Acad Sci USA. 2011;108:13722-13727.
165. Davani B, Khan A, Hult M, et al. Type 1 11β-hydroxysteroid dehydrogenase mediates glucocorticoid activation and insulin release in pancreatic islets. J Biol Chem. 2000; 275:34841-34844.
166. Duplomb L, Lee Y, Wang MY, et al. Increased expression and activity of 11β-HSD-1 in diabetic islets and prevention with troglitazone. Biochem Biophys Res Commun. 2004; 313:594-599.
167. Turban S, Liu X, Ramage L, et al. Optimal elevation of β-cell 11β-hydroxysteroid dehydrogenase type 1 is a compensatory mechanism that prevents high fat diet-induced β-cell failure. Diabetes. 2012;61:642-652.
168. Du J, Wang Y, Hunter R, et al. Dynamic regulation of mitochondrial function by glucocorticoids. Proc Natl Acad Sci USA. 2009;106:3543-3548.
169. Pivonello R, Faggiano A, Lombardi G, Colao A. The metabolic syndrome and cardiovascular risk in Cushing's syndrome. Endocrinol Metab Clin North Am. 2005;34:327-339, viii.
170. Hermanowski-Vosatka A, Balkovec JM, Cheng K, et al. 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med. 2005;202:517-527.
171. Borski RJ, Hyde GN, Fruchtman S. Signal transduction mechanisms mediating rapid, nongenomic effects of cortisol on prolactin release. Steroids. 2002;67:539-548.
172. Simoncini T, Maffei S, Basta G, et al. Estrogens and glucocorticoids inhibit endothelial vascular cell adhesion molecule-1 expression by different transcriptional mechanisms. Circ Res. 2000;87:19-25.
173. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs.NEngl J Med. 2005;353:1711-1723.
174. Brem AS, Bina RB, King TC, Morris DJ. Localization of 2 11β-OH steroid dehydrogenase isoforms in aortic endothelial cells. Hypertension. 1998;31:459-462.
175. Walker BR, Yau JL, Brett LP, et al. 11-β-Hydroxysteroid dehydrogenase in vascular smooth-muscle and heart: implications for cardiovascular responses to glucocorticoids. Endocrinology. 1991;129:3305-3312.
176. Walker BR, Connacher AA, Webb DJ, Edwards CR. Glucocorticoids and blood pressure: a role for the cortisol/ cortisone shuttle in the control of vascular tone in man. Clin Sci (Lond). 1992;83:171-178.
177. Brem AS, Bina RB, King T, Morris DJ. Bidirectional activity of 11 β-hydroxysteroid dehydrogenase in vascular smooth muscle cells. Steroids. 1995;60:406-410.
178. Atalar F, Vural B, Ciftci C, et al. 11 β-Hydroxysteroid dehydrogenase type 1 gene expression is increased in ascending aorta tissue of metabolic syndrome patients with coronary artery disease. Genet Mol Res. 2012;11:3122-3132.
179. Folkman J, Langer R, Linhardt RJ, Haudenschild C, Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science. 1983;221:719-725.
180. Logie JJ, Ali S, Marshall KM, Heck MM, Walker BR, Hadoke PW. Glucocorticoid-mediated inhibition of angiogenic changes in human endothelial cells is not caused by reductions in cell proliferation or migration. PLoS One. 2010;5:e14476.
181. Hasan Q, Tan ST, Gush J, Peters SG, Davis PF. Steroid therapy of a proliferating hemangioma: histochemical and molecular changes. Pediatrics. 2000;105:117-121.
182. Yano A, Fujii Y, Iwai A, Kageyama Y, Kihara K. Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res. 2006;12:3003-3009.
183. Dietrich K, Schned A, Fortuny J, et al. Glucocorticoid therapy and risk of bladder cancer. Br J Cancer. 2009;101: 1316-1320.
184. Michailidou Z, Turban S, Miller E, et al. Increased angiogenesis protects against adipose hypoxia and fibrosis in metabolic disease-resistant 11β-hydroxysteroid dehydrogenase type 1 (HSD1)-deficient mice. J Biol Chem. 2012; 287:4188-4197.
185. Small GR, Hadoke PW, Sharif I, et al. Preventing local regeneration of glucocorticoids by 11 β-hydroxysteroid dehydrogenase type 1 enhances angiogenesis. Proc Natl Acad Sci USA. 2005;102:12165-12170.
186. van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15:993-1000.
187. Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med. 2011;365:62-70.
188. Cooper MS. Sensitivity of bone to glucocorticoids. Clin Sci (Lond). 2004;107:111-123.
189. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000;21:115-137.
190. Rauch A, Seitz S, Baschant U, et al. Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab. 2010;11:517-531.
191. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998;102:274-282.
192. Bellows CG, Ciaccia A, Heersche JN. Osteoprogenitor cells in cell populations derived from mouse and rat calvaria differ in their response to corticosterone, cortisol, and cortisone. Bone. 1998;23:119-125.
193. Bland R, Worker CA, Noble BS, et al. Characterization of 11β-hydroxysteroid dehydrogenase activity and corticosteroid receptor expression in human osteosarcoma cell lines. J Endocrinol. 1999;161:455-464.
194. Eyre LJ, Rabbitt EH, Bland R, et al. Expression of 11 β-hydroxysteroid dehydrogenase in rat osteoblastic cells: pre-receptor regulation of glucocorticoid responses in bone. J Cell Biochem. 2001;81:453-462.
195. Cooper MS, Walker EA, Bland R, FraserWD,HewisonM, Stewart PM. Expression and functional consequences of 11β-hydroxysteroid dehydrogenase activity in human bone. Bone. 2000;27:375-381.
196. Eijken M, Hewison M, Cooper MS, et al. 11 β-Hydroxysteroid dehydrogenase expression and glucocorticoid synthesis are directed by a molecular switch during osteoblast differentiation. Mol Endocrinol. 2005;19:621-631.
197. Cooper MS, Syddall HE, Fall CH, et al. Circulating cortisone levels are associated with biochemical markers of bone formation and lumbar spine BMD: the Hertfordshire Cohort Study. Clin Endocrinol (Oxf). 2005;62:692-697.
198. Cooper MS, Bujalska I, Rabbitt E, et al. Modulation of 11β-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. J Bone Miner Res. 2001;16:1037-1044.
199. Kaur K, Hardy R, AhasanMM,et al. Synergistic induction of local glucocorticoid generation by inflammatory cytokines and glucocorticoids: implications for inflammation associated bone loss. Ann Rheum Dis. 2010;69:1185-1190.
200. Justesen J, Mosekilde L, Holmes M, et al. Mice deficient in 11β-hydroxysteroid dehydrogenase type 1 lack bone marrow adipocytes, but maintain normal bone formation. Endocrinology. 2004;145:1916-1925.
201. Sher LB, Harrison JR, Adams DJ, Kream BE. Impaired cortical bone acquisition and osteoblast differentiation in mice with osteoblast-targeted disruption of glucocorticoid signaling. Calcif Tissue Int. 2006;79:118-125.
202. Cooper MS, Blumsohn A, Goddard PE, et al. 11β-Hydroxysteroid dehydrogenase type 1 activity predicts the effects of glucocorticoids on bone. J Clin Endocrinol Metab. 2003;88:3874-3877.
203. Hofbauer LC, Gori F, Riggs BL, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoidinduced osteoporosis. Endocrinology. 1999;140:4382-4389.
204. Cooper MS, Rabbitt EH, Goddard PE, BartlettWA,Hewison M, Stewart PM. Osteoblastic 11β-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. J Bone Miner Res. 2002;17:979-986.
205. Li WJ, Gao L, Wang Y, Duan T, Myatt L, Sun K. Enhancement of cortisol-induced 11 β-hydroxysteroid dehydrogenase type 1 expression by interleukin 1β in culturedhuman chorionic trophoblast cells. Endocrinology. 2006;147: 2490-2495.
206. Ahasan MM, Hardy R, Jones C, et al. Inflammatory regulation of glucocorticoid metabolism in mesenchymal stromal cells. Arthritis Rheum. 2012;64:2404-2413.
207. Thieringer R, Le Grand CB, Carbin L, et al. 11β-Hydroxysteroid dehydrogenase type 1 is induced in human monocytes upon differentiation to macrophages. J Immunol. 2001;167:30-35.
208. Freeman L, Hewison M, Hughes SV, et al. Expression of 11β-hydroxysteroid dehydrogenase type 1 permits regulation of glucocorticoid bioavailability by human dendritic cells. Blood. 2005;106:2042-2049.
209. Zhang TY, Ding X, Daynes RA. The expression of 11 β-hydroxysteroid dehydrogenase type I by lymphocytes provides a novel means for intracrine regulation of glucocorticoid activities. J Immunol. 2005;174:879-889.
210. Gilmour JS, Coutinho AE, Cailhier JF, et al. Local amplification of glucocorticoids by 11 β-hydroxysteroid dehydrogenase type 1 promotes macrophage phagocytosis of apoptotic leukocytes. J Immunol. 2006;176:7605-7611.
211. Zhang TY, Daynes RA. Macrophages from 11β-hydroxysteroid dehydrogenase type 1-deficient mice exhibit an increased sensitivity to lipopolysaccharide stimulation due to TGF-β-mediated up-regulation of SHIP1 expression. J Immunol. 2007;179:6325-6335.
212. Coutinho AE, Gray M, Brownstein DG, et al. 11 β-Hydroxysteroid dehydrogenase type 1, but not type 2, deficiency worsens acute inflammation and experimental arthritis in mice. Endocrinology. 2012;153:234-240.
213. Hardy R, Rabbitt EH, Filer A, et al. Local and systemic glucocorticoid metabolism in inflammatory arthritis. Ann Rheum Dis. 2008;67:1204-1210.
214. ZbankovaS, Bryndova J, Leden P,KmentM,Svec A, Pacha J. 11β-Hydroxysteroid dehydrogenase 1 and 2 expression in colon from patients with ulcerative colitis. J Gastroenterol Hepatol. 2007;22:1019-1023.
215. Stegk JP, Ebert B, Martin HJ, Maser E. Expression profiles of human 11β-hydroxysteroid dehydrogenases type 1 and type 2 in inflammatory bowel diseases. Mol Cell Endocrinol. 2009;301:104-108.
216. Cooper MS, Kriel H, Sayers A, et al. Can 11β-hydroxysteroid dehydrogenase activity predict the sensitivity of doi: 10.1210/er.2012-1050 edrv.endojournals.org 551 bone to therapeutic glucocorticoids in inflammatory bowel disease? Calcif Tissue Int. 2011;89:246-251.
217. Bailey E, GreavesMS,MurphyD, West HF.Corticosteroid metabolism and rheumatoid arthritis. Ann Rheum Dis. 1966;25:516-524.
218. Schmidt M, Weidler C, Naumann H, Anders S, Scholmerich J, Straub RH. Reduced capacity for the reactivation of glucocorticoids in rheumatoid arthritis synovial cells: possible role of the sympathetic nervous system? Arthritis Rheum. 2005;52:1711-1720.
219. Ergang P, Leden P, Vagnerova K, et al. Local metabolism of glucocorticoids and its role in rat adjuvant arthritis. Mol Cell Endocrinol. 2010;323:155-160.
220. Brown ES. Effects of glucocorticoids on mood, memory, and the hippocampus. Treatment and preventive therapy. Ann NY Acad Sci. 2009;1179:41-55.
221. Starkman MN, Gebarski SS, Berent S, Schteingart DE. Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing's syndrome. Biol Psychiatry. 1992;32:756-765.
222. Wilner AP, de Varennes B, Gregoire PA, Lupien S, Pruessner JC. Glucocorticoids and hippocampal atrophy after heart transplantation. Ann Thorac Surg. 2002;73:1965-1967.
223. Almeida OF, Conde GL, Crochemore C, et al. Subtle shifts in the ratio between pro-and antiapoptotic molecules after activation of corticosteroid receptors decide neuronal fate. FASEB J. 2000;14:779-790.
224. Gould E, Tanapat P, McEwen BS, Flugge G, Fuchs E. Proliferation of granule cell precursors in the dentate gyrus of adult monkeys is diminished by stress. Proc Natl Acad Sci USA. 1998;95:3168-3171.
225. Armanini MP, Hutchins C, Stein BA, Sapolsky RM. Glucocorticoid endangerment of hippocampal neurons is NMDA-receptor dependent. Brain Res. 1990;532:7-12.
226. Schubert MI, Kalisch R, Sotiropoulos I, et al. Effects of altered corticosteroid milieu on rat hippocampal neurochemistry and structure-an in vivo magnetic resonance spectroscopy and imaging study. J Psychiatr Res. 2008; 42:902-912.
227. Lee KW, Kim JB, Seo JS, et al. Behavioral stress accelerates plaque pathogenesis in the brain of Tg2576 mice via generation of metabolic oxidative stress. J Neurochem. 2009; 108:165-175.
228. Catania C, Sotiropoulos I, Silva R, et al. The amyloidogenic potential and behavioral correlates of stress. Mol Psychiatry. 2009;14:95-105.
229. Green KN, Billings LM, Roozendaal B, McGaugh JL, LaFerla FM. Glucocorticoids increase amyloid-β and tau pathology in a mouse model of Alzheimer's disease. J Neurosci. 2006;26:9047-9056.
230. van Rossum EF, de Jong FJ, Koper JW, et al. Glucocorticoid receptor variant and risk of dementia and white matter lesions. Neurobiol Aging. 2008;29:716-723.
231. Rauz S, Walker EA, Hughes SV, et al. Serum-and glucocorticoid-regulated kinase isoform-1 and epithelial sodium channel subunits in human ocular ciliary epithelium. Invest Ophthalmol Vis Sci. 2003;44:1643-1651.
232. Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics. I. Effect of dexamethasone in normal eye. Arch Ophthalmol. 1963;70:482-491.
233. Armaly MF, Becker B. Intraocular pressure response to topical corticosteroids. Fed Proc. 1965;24:1274-1278.
234. Starka L, Obenberger J. Steroids and intraocular pressure. J Steroid Biochem. 1976;7:979-983.
235. Kiehna EN, Keil M, Lodish M, Stratakis C, Oldfield EH. Pseudotumor cerebri after surgical remission of Cushing's disease. J Clin Endocrinol Metab. 2010;95:1528-1532.
236. Sinclair AJ, Ball AK, Burdon MA, et al. Exploring the pathogenesis of IIH: an inflammatory perspective. J Neuroimmunol. 2008;201-202:212-220.
237. Wyrwoll CS, Holmes MC, Seckl JR. 11β-Hydroxysteroid dehydrogenases and the brain: from zero to hero, a decade of progress. Front Neuroendocrinol. 2011;32:265-286.
238. Rauz S, Walker EA, Shackleton CH, Hewison M, Murray PI, Stewart PM. Expression and putative role of 11 β-hydroxysteroid dehydrogenase isozymes within the human eye. Invest Ophthalmol Vis Sci. 2001;42:2037-2042.
239. Rajan V, Edwards CR, Seckl JR. 11 β-Hydroxysteroid dehydrogenase in cultured hippocampal cells reactivates inert 11-dehydrocorticosterone, potentiating neurotoxicity. J Neurosci. 1996;16:65-70.
240. Gomez-Sanchez EP, Romero DG, de Rodriguez AF, Warden MP, Krozowski Z, Gomez-Sanchez CE. Hexose-6-phosphate dehydrogenase and 11β-hydroxysteroid dehydrogenase-1 tissue distribution in the rat. Endocrinology. 2008;149:525-533.
241. Wyrwoll CS, Holmes MC. Prenatal excess glucocorticoid exposure and adult affective disorders: a role for serotonergic and catecholamine pathways. Neuroendocrinology. 2012;95:47-55.
242. Sooy K, Webster SP, Noble J, et al. Partial deficiency or short-term inhibition of 11β-hydroxysteroid dehydrogenase type 1 improves cognitive function in aging mice. J Neurosci. 2010;30:13867-13872.
243. Sandeep TC, Yau JL, MacLullich AM, et al. 11β-Hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc Natl Acad Sci USA. 2004;101:6734-6739.
244. Yau JL, Noble J, Kenyon CJ, et al. Lack of tissue glucocorticoid reactivation in 11β-hydroxysteroid dehydrogenase type 1 knockout mice ameliorates age-related learning impairments. Proc Natl Acad Sci USA. 2001;98:4716-4721.
245. Yau JL, McNair KM, Noble J, et al. Enhanced hippocampal long-term potentiation and spatial learning in aged 11β-hydroxysteroid dehydrogenase type 1 knock-out mice. J Neurosci. 2007;27:10487-10496.
246. Rauz S, Cheung CM, Wood PJ, et al. Inhibition of 11β-hydroxysteroid dehydrogenase type 1 lowers intraocular pressure in patients with ocular hypertension.QJM. 2003; 96:481-490.
247. Sinclair AJ, Walker EA, Burdon MA, et al. Cerebrospinal fluid corticosteroid levels and cortisol metabolism in patients with idiopathic intracranial hypertension: a link between 11β-HSD1 and intracranial pressure regulation? J Clin Endocrinol Metab. 2010;95:5348-5356.
248. Van Cauter E, Leproult R, Kupfer DJ. Effects of gender and age on the levels and circadian rhythmicity of plasma cortisol. J Clin Endocrinol Metab. 1996;81:2468-2473.
249. Sapolsky RM, Krey LC, McEwen BS. The neuroendocri-nology of stress and aging: the glucocorticoid cascade hypothesis. Endocr Rev. 1986;7:284-301.
250. Giordano R, Bo M, Pellegrino M, et al. Hypothalamuspituitary-adrenal hyperactivity in human aging is partially refractory to stimulation by mineralocorticoid receptor blockade. J Clin Endocrinol Metab. 2005;90:5656-5662.
251. Iranmanesh A, Lizarralde G, Veldhuis JD. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J Clin Endocrinol Metab. 1991;73:1081-1088.
252. Landin-Wilhelmsen K, Wilhelmsen L, Lappas G, et al. Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endocrinol (Oxf). 1994;41:351-357.
253. Payette H, Roubenoff R, Jacques PF, et al. Insulin-like growth factor-1 and interleukin 6 predict sarcopenia in very old community-living men and women: the Framingham Heart Study. J AmGeriatr Soc. 2003;51:1237-1243.
254. Pleasure DE, Walsh GO, Engel WK. Atrophy of skeletal muscle in patients with Cushing's syndrome. Arch Neurol. 1970;22:118-125.
255. Vignos PJ Jr, Greene R. Oxidative respiration of skeletal muscle in experimental corticosteroid myopathy. J Lab Clin Med. 1973;81:365-378.
256. Djaldetti M, Gafter U, Fishman P. Ultrastructural observations in myopathy complicating Cushing's disease.AmJ Med Sci. 1977;273:273-277.
257. Ravaglia G, Forti P, Maioli F, Boschi F, Cicognani A, Gasbarrini G. Measurement of body fat in healthy elderly men: a comparison of methods. J Gerontol A Biol Sci Med Sci. 1999;54:M70-M76.
258. Kuzuya M, Ando F, Iguchi A, Shimokata H. Changes in serum lipid levels during a 10 year period in a large Japanese population. A cross-sectional and longitudinal study. Atherosclerosis. 2002;163:313-320.
259. Andersson T, Simonyte K, Andrew R, et al. Tissue-specific increases in 11β-hydroxysteroid dehydrogenase type 1 in normal weight postmenopausal women. PLoS One. 2009; 4:e8475.
260. Weinstein RS, Wan C, Liu Q, et al. Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice. Aging Cell. 2010;9:147-161.
261. Fisher GJ, Varani J, Voorhees JJ. Looking older: fibroblast collapse and therapeutic implications. Arch Dermatol. 2008;144:666-672.
262. Farage MA, Miller KW, Berardesca E, Maibach HI. Clinical implications of aging skin: cutaneous disorders in the elderly. Am J Clin Dermatol. 2009;10:73-86.
263. Yanovski JA, Cutler GB Jr. Glucocorticoid action and the clinical features of Cushing's syndrome. Endocrinol Metab Clin North Am. 1994;23:487-509.
264. Schoepe S, Schacke H, May E, Asadullah K. Glucocorticoid therapy-induced skin atrophy. Exp Dermatol. 2006; 15:406-420.
265. Kolbe L, Kligman AM, Schreiner V, Stoudemayer T. Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin. Skin Res Technol. 2001;7:73-77.
266. Tiganescu A, Walker EA, Mayes AE, Stewart PM. 11 β-Hydroxysteroid dehydrogenase type 1 increases with age and photoexposure in human skin ex vivo. J Invest Dermatol. 2011;131(suppl 1):S91 (Abstract 541).
267. Low LF, Brodaty H, Edwards R, et al. The prevalence of "cognitive impairment no dementia" in community-dwelling elderly: a pilot study. Aust N Z J Psychiatry. 2004;38: 725-731.
268. Meaney MJ, O'Donnell D, Rowe W, et al. Individual differences in hypothalamic-pituitary-adrenal activity in later life and hippocampal aging. Exp Gerontol. 1995;30:229-251.
269. Landfield PW, Waymire JC, Lynch G. Hippocampal aging and adrenocorticoids: quantitative correlations. Science. 1978;202:1098-1102.
270. MacLullich AM, Deary IJ, Starr JM, Ferguson KJ, Wardlaw JM, Seckl JR. Plasma cortisol levels, brain volumes and cognition in healthy elderly men. Psychoneuroendocrinology. 2005;30:505-515.
271. Issa AM, Rowe W, Gauthier S, Meaney MJ. Hypothalamic-pituitary-adrenal activity in aged, cognitively impaired and cognitively unimpaired rats. J Neurosci. 1990;10: 3247-3254.
272. Holmes MC, Carter RN, Noble J, et al. 11β-Hydroxysteroid dehydrogenase type 1 expression is increased in the aged mouse hippocampus and parietal cortex and causes memory impairments. J Neurosci. 2010;30:6916-6920.
273. Schweizer RA, Atanasov AG, Frey BM, Odermatt A. A rapid screening assay for inhibitors of 11β-hydroxysteroid dehydrogenases (11β-HSD): flavanone selectively inhibits 11β-HSD1 reductase activity. Mol Cell Endocrinol. 2003; 212:41-49.
274. Diederich S, Grossmann C, Hanke B, et al. In the search for specific inhibitors of human 11 β-hydroxysteroid-dehydrogenases (11 β-HSDs): chenodeoxycholic acid selectively inhibits 11 β-HSD-I. Eur J Endocrinol. 2000;142: 200-207.
275. Latif SA, Pardo HA, Hardy MP, Morris DJ. Endogenous selective inhibitors of 11 β-hydroxysteroid dehydrogenase isoforms 1 and 2 of adrenal origin. Mol Cell Endocrinol. 2005;243:43-50.
276. Andrews RC, Rooyackers O, Walker BR. Effects of the 11 β-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab. 2003;88:285-291.
277. Tomlinson JW, Sherlock M, Hughes B, et al. Inhibition of 11β-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis. J Clin Endocrinol Metab. 2007; 92:857-864.
278. Thomson Reuters. The changing role of chemistry in drug discovery. International Year of Chemistry (IYC 2011) report. http:thomsonreuters.com/content/science/pdf/ls/iyc2011.pdf.
279. Boyle CD, Kowalski TJ. 11β-Hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents. Expert Opin Ther Pat. 2009;19:801-825.
280. Aoyagi A, Ito-Kobayashi M, Ono Y, et al. Colletoic acid, a novel 11β-hydroxysteroid dehydrogenase type 1 inhib itor from Colletotrichum gloeosporioides SANK 21404. J Antibiot (Tokyo). 2008;61:136-141.
281. Caille S, Cui S, Hwang TL, Wang X, FaulMM.Twoasymmetric syntheses ofAMG221, an inhibitor of 11β-hydroxysteroid dehydrogenase type 1. J Org Chem. 2009;74: 3833-3842.
282. Cheng H, Hoffman J, Le P, et al. The development andSAR of pyrrolidine carboxamide 11β-HSD1 inhibitors. Bioorg Med Chem Lett. 2010;20:2897-2902.
283. Coppola GM, Kukkola PJ, Stanton JL, et al. Perhydroquinolylbenzamides as novel inhibitors of 11β-hydroxysteroid dehydrogenase type 1. JMedChem. 2005;48:6696-6712.
284. Gaware R, Khunt R, Czollner L, et al. Synthesis of new glycyrrhetinic acid derived ring A azepanone, 29-urea and 29-hydroxamic acid derivatives as selective 11β-hydroxysteroid dehydrogenase 2 inhibitors. Bioorg Med Chem. 2011;19:1866-1880.
285. Gibbs JP, Emery MG, McCaffery I, et al. Population pharmacokinetic/ pharmacodynamic model of subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity after oral administration of AMG 221, a selective 11β-HSD1 inhibitor. J Clin Pharmacol. 2011;51: 830-841.
286. JohanssonL,FotschC,BartbergerMD,etal.2-Amino-1,3-thiazol-4(5H)-ones as potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structureanddemonstrationofpharmacodynamiceffects inC57Bl/6 mice. J Med Chem. 2008;51:2933-2943.
287. Kim SH, Kwon SW, Chu SY, et al. Identification of cyclic sulfonamide derivatives with an acetamide group as 11β-hydroxysteroid dehydrogenase 1 inhibitors. Chem Pharm Bull (Tokyo). 2011;59:46-52.
288. Lepifre F, Christmann-Franck S, Roche D, et al. Discovery and structure-guided drug design of inhibitors of 11β-hydroxysteroid-dehydrogenase type I based on a spirocarboxamide scaffold. Bioorg Med Chem Lett. 2009;19: 3682-3685.
289. Maletic M, Leeman A, Szymonifka M, et al. Bicyclo[2.2.2]octyltriazole inhibitors of 11β-hydroxysteroid dehydrogenase type 1. Pharmacological agents for the treatment of metabolic syndrome. Bioorg Med Chem Lett. 2011;21:2568-2572.
290. Rohde JJ, Pliushchev MA, Sorensen BK, et al. Discovery and metabolic stabilization of potent and selective 2-amino-N-(adamant-2-yl)acetamide11β-hydroxysteroiddehydrogenasetype 1 inhibitors. J Med Chem. 2007;50:149-164.
291. Stanetty C, Czollner L, Koller I, et al. Synthesis of novel 3-amino and 29-hydroxamic acid derivatives of glycyrrhetinic acid as selective 11β-hydroxysteroid dehydrogenase 2 inhibitors. Bioorg Med Chem. 2010;18:7522-7541.
292. Sun D, Wang M, Wang Z. Small molecule 11β-hydroxysteroid dehydrogenase type 1 inhibitors. Curr Top Med Chem. 2011;11:1464-1475.
293. Veniant MM, Hale C, Hungate RW, et al. Discovery of a potent, orally active 11β-hydroxysteroid dehydrogenase type 1 inhibitor for clinical study: identification of (S)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5 H)-one (AMG 221). J Med Chem. 2010;53: 4481-4487.
294. Vicker N, Su X, Ganeshapillai D, et al. Novel non-steroidal inhibitors of human 11β-hydroxysteroid dehydrogenase type 1. J Steroid Biochem Mol Biol. 2007;104:123-129.
295. Wan ZK, Chenail E, Li HQ, et al. Synthesis of potent and orally efficacious 11β-hydroxysteroid dehydrogenase type 1 inhibitor HSD-016. J Org Chem. 2011;76:7048-7055.
296. Wang H, Robl JA, Hamann LG, et al. Generation of 3,8-substituted 1,2,4-triazolopyridines as potent inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1). Bioorg Med Chem Lett. 2011;21:4146-4149.
297. Ye YL, Zhou Z, Zou HJ, et al. Discovery of novel dual functional agent as PPARγ agonist and 11β-HSD1 inhibitor for the treatment of diabetes. BioorgMedChem. 2009; 17:5722-5732.
298. Zhao B, Lian Q, Chu Y, Hardy DO, Li XK, Ge RS. The inhibition of human and rat 11β-hydroxysteroid dehydrogenase 2 by perfluoroalkylated substances. J Steroid Biochem Mol Biol. 2011;125:143-147.
299. Barf T, Vallgarda J, Emond R, et al. Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11β-hydroxysteroid dehydrogenase type 1. J Med Chem. 2002; 45:3813-3815.
300. Alberts P, Engblom L, Edling N, et al. Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia. 2002;45:1528-1532.
301. Alberts P, Nilsson C, Selen G, et al. Selective inhibition of 11 β-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology. 2003;144:4755-4762.
302. Feng Y, Huang SL, Dou W, et al. Emodin, a natural product, selectively inhibits 11β-hydroxysteroid dehydrogenase type 1 and ameliorates metabolic disorder in dietinduced obese mice. Br J Pharmacol. 2010;161:113-126.
303. Park JS, Rhee SD, Kang NS, et al. Anti-diabetic and antiadipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone (KR-66344). Biochem Pharmacol. 2011;81:1028-1035.
304. Berthiaume M, Laplante M, Festuccia WT, et al. 11β-HSD1 inhibition improves triglyceridemia through reduced liver VLDL secretion and partitions lipids toward oxidative tissues. Am J Physiol Endocrinol Metab. 2007; 293:E1045-E1052.
305. Berthiaume M, Laplante M, Festuccia W, et al. Depotspecific modulation of rat intraabdominal adipose tissue lipid metabolism by pharmacological inhibition of 11β-hydroxysteroid dehydrogenase type 1. Endocrinology. 2007;148:2391-2397.
306. Sundbom M, Kaiser C, Bjorkstrand E, et al. Inhibition of 11βHSD1 with the S-phenylethylaminothiazolone BVT116429 increases adiponectin concentrations and improves glucose homeostasis in diabetic KKAy mice. BMC Pharmacol. 2008;8:3.
307. Berthiaume M, Laplante M, Festuccia WT, Berger JP, Thieringer R, Deshaies Y. Additive action of 11β-HSD1 inhibition and PPAR-γ agonism on hepatic steatosis and triglyceridemia in diet-induced obese rats. Int J Obes (Lond). 2009;33:601-604.
308. Berthiaume M, Laplante M, Festuccia WT, Berger JP, Thieringer R, Deshaies Y. Preliminary report: pharmaco-logic 11β-hydroxysteroid dehydrogenase type 1 inhibition increases hepatic fat oxidation in vivo and expression of related genes in rats fed an obesogenic diet. Metabolism. 2010;59:114-117.
309. Wang L, Liu J, Zhang A, et al. BVT.2733, a selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, attenuates obesity and inflammation in diet-induced obese mice. PLoS One. 2012;7:e40056.
310. Lloyd DJ, Helmering J, Cordover D, et al. Antidiabetic effects of 11β-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis. Diabetes Obes Metab. 2009;11:688-699.
311. Edgerton DS, Basu R, Ramnanan CJ, et al. Effect of 11 β-hydroxysteroid dehydrogenase-1 inhibition on hepatic glucose metabolism in the conscious dog. Am J Physiol Endocrinol Metab. 2010;298:E1019-E1026.
312. Bhat BG, Hosea N, Fanjul A, et al. Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4'-cyano-biphenyl-4-sulfonic acid (6-amino-pyridin-2-yl)-amide (PF-915275), an inhibitor of 11 -hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys. J Pharmacol Exp Ther. 2008;324:299-305.
313. National Institutes of Health. A study of the effect of INCB013739 on cortisone reducing enzyme activity in obese people predisposed to diabetes. 2012. http:www.clinicaltrials.gov/ct2/show/NCT00398619.
314. Rosenstock J, Banarer S, Fonseca VA, et al. The 11-β-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemiainpatientswithtype2diabetesinadequatelycontrolled by metformin monotherapy. Diabetes Care. 2010;33: 1516-1522.
315. Feig PU, Shah S, Hermanowski-Vosatka A, et al. Effects of an 11 β-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes Obes Metab. 2011;13: 498-504.
316. Shah S, Hermanowski-Vosatka A, Gibson K, et al. Efficacy and safety of the selective 11β-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension. J Am Soc Hypertens. 2011;5:166-176.
317. Courtney R, Stewart PM, Toh M, Ndongo MN, Calle RA, Hirshberg B. Modulation of 11 β-hydroxysteroid dehydrogenase (11 β HSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11 β HSD1 inhibitor. J Clin Endocrinol Metab. 2008;93:550-556.
318. Nixon M, Wake DJ, Livingstone DE, et al. Salicylate downregulates 11β-HSD1 expression in adipose tissue in obese mice and in humans, mediating insulin sensitization. Diabetes. 2012;61:790-796.